The first course of treatment failed to achieve remission, and next-generation sequencing (NGS) showed SRSF2, SETBP1, RUNX1, and IDH2 gene mutations which are reported to be enriched in post-MPN AML (9). Here, RUNX1 is linked to acute myeloid leukemia.